Affordable Access

Publisher Website

Ganglioside GM2/GD2 Synthetase mRNA Is a Marker for Detection of Infrequent Neuroblastoma Cells in Bone Marrow

American Journal Of Pathology
Publication Date
DOI: 10.1016/s0002-9440(10)61721-x
  • Hoon Et Al
  • Medicine


GalNAcβ1-4(NeuAcα2-3)Galβ1-4Glcβ1-Cer (GM2)/GalNAcβ1-4(NeuAcα2-8NeuAcα2-3)Galβ1-4Glcβ1-1Cer (GD2) synthetase [β-1,4- N-acetyl-galactosaminyl transferase (GalNAc-T)] mRNA, which encodes a key glycosyltransferase for ganglioside GD2 synthesis, was assessed as a molecular marker for detecting metastatic neuroblastoma cells in bone marrow (BM). GalNAc-T mRNA expression by neuroblastoma cell lines ( n = 15), primary untreated neuroblastoma tumors ( n = 29), morphologically normal BM ( n = 22), peripheral blood stem cells ( n = 10) from patients with cancers other than neuroblastoma, and blood mononuclear cells from normal donors ( n = 17) was assessed by using reverse transcriptase-polymerase chain reaction (RT-PCR) and electrochemiluminescence detection assay (RT-PCR/ECL). BM harvested from 15 neuroblastoma patients was tested before and after ex vivo immunomagnetic bead purging, and results were compared to immunocytological analysis of the same specimens. All neuroblastoma cell lines (mean, 653 × 10 3 ECL units) and primary tumors (mean, 683 × 10 3ECL units) were positive for significant expression of GalNAc-T mRNA compared to normal blood and BM cells. The RT-PCR/ECL assay could detect GalNAc-T mRNA in 100 pg of total RNA, and in a mixture of one neuroblastoma cell among 10 7 normal BM or blood cells. Eight of 15 autologous BM cells harvested from patients with neuroblastoma had tumor cells detectable by immunocytology, and all 15 were positive for GalNAc-T mRNA. After ex vivo purging, none of the BM cells was immunocytology-positive, but six remained positive by the RT-PCR/ECL assay. GalNAc-T mRNA provides a specific and sensitive molecular marker for RT-PCR/ECL detection of infrequent neuroblastoma cells in BM.

There are no comments yet on this publication. Be the first to share your thoughts.